Galderma announces FDA approval of Restylane Silk as the first HA dermal filler approved for injection via cannula.
Galderma, a global company focused on medical solutions in skin health, announced it has received U.S. Food and Drug Administration (FDA) approval for the use of a small blunt tip cannula with Restylane Silk for lip augmentation.
Restylane Silk was the first FDA-approved hyaluronic acid (HA) dermal filler specifically designed for lip augmentation and the smoothing of wrinkles around the mouth in patients 21 years of age and older and is now the first HA dermal filler to be approved for lip injection via cannula.
A small blunt tip cannula is a thin, flexible tube with a small opening on the side that can provide an effective means to inject HA dermal fillers in the lips. This approval for Restylane Silk expands the array of approved lip injection techniques for medical professionals.
“In the ever-evolving landscape of aesthetic procedures, medical professionals are continuously looking for new tools and treatment options to ensure our patients are receiving optimal treatment outcomes for their specific needs,” said Sabrina Fabi, MD, a San Diego-based Dermatologist. “The ability to use a cannula is a welcome addition to my toolkit, as studies have shown that a small blunt tip cannula demonstrates a suitable safety profile, while achieving the desired fullness to the upper and lower lips.”
“A commitment to continuous innovation in support of aesthetic professionals to achieve high patient satisfaction with natural looking results is our core focus,” said Alisa Lask, VP & General Manager of Galderma’s U.S. Aesthetic & Corrective business. “The Restylane family currently offers the broadest offering of HA facial dermal fillers in the U.S. With the launch of Restylane® Refyne and Restylane Defyne earlier this year and this new approval, 2017 is an exciting year for patients and aesthetic professionals who use the Restylane brands.”
Filed Under: Drug Discovery